Kirit Patel, MD
Addiction Medicine · Shreveport, LANPI 1477512309
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $25,200 of the $37,246 with a category attached, or 67.7%. 22 manufacturers reported payments, led by AstraZeneca at 53.4% of the total. Reporting peaked in 2021 at $13,035 and has fallen 95.9% since, to $540 in 2025.
Across 468 payments — averaging $79.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$20K
- GSK$13K
- Daiichi Sankyo Inc.$2K
- Novo Nordisk$711
- Amgen$645
- Phathom Pharmaceuticals, Inc.$185
- plus $966 from 16 others
What the payments were for
- Speaking & faculty fees$25,20068%
- Travel & lodging$790%
- Food & beverage$11,96832%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 171 | $19,889 |
| GSK | 94 | $12,518 |
| Daiichi Sankyo Inc. | 112 | $2,333 |
| Novo Nordisk | 42 | $711 |
| Amgen | 8 | $645 |
| Phathom Pharmaceuticals, Inc. | 4 | $185 |
| Mylan Specialty L.p. | 2 | $143 |
| Biodelivery Sciences International, Inc. | 11 | $134 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Smith+Nephew | 1 | $124 |
| Pfizer | 6 | $104 |
| Novartis | 5 | $73 |
| Otsuka America Pharmaceutical, Inc. | 1 | $49 |
| Merck | 1 | $37 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $37 |
| Stryker | 1 | $30 |
| Alpha Cognition USA, Inc. | 1 | $28 |
| Sage Therapeutics, LLC | 1 | $22 |
| E.r. Squibb & Sons, L.L.C. | 1 | $19 |
| Alkermes, Inc. | 1 | $16 |
| Avanir Pharmaceuticals, Inc. | 1 | $13 |
| Sanofi-aventis U.S. LLC | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,246 in reported general payments places this provider in the 85th percentile of 28 addiction medicine providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 107 | $100,526 |
| EliquisApixaban | 258 | $90,506 |
| RybelsusSemaglutide | 51 | $68,000 |
| JardianceEmpagliflozin | 114 | $66,223 |
| OzempicSemaglutide | 52 | $60,513 |
| FarxigaDapagliflozin Propanediol | 58 | $41,167 |
| EntrestoSacubitril/Valsartan | 60 | $36,622 |
| TrulicityDulaglutide | 36 | $17,460 |
| MounjaroTirzepatide | 15 | $15,504 |
| MyrbetriqMirabegron | 43 | $12,342 |
| AbrysvoRsv Vacc, Pref A And Pref B/Pf | 39 | $12,204 |
| Xigduo XrDapaglifloz Propaned/Metformin | 18 | $11,827 |
| SymbicortBudesonide/Formoterol Fumarate | 29 | $10,468 |
| LinzessLinaclotide | 19 | $10,316 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 24 | $7,471 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskRybelsus, Ozempic | $711 | $128,512103 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $12,518 | $107,997131 claims |
| PfizerEliquis, Abrysvo | $104 | $102,710297 claims |
| AstraZenecaFarxiga, Symbicort, Lokelma | $19,889 | $55,896100 claims |
| NovartisEntresto | $73 | $36,62260 claims |
| MerckJanuvia | $37 | $5,01514 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 28 addiction medicine providers in Louisiana.
Other addiction medicine in Shreveport
- Richard SipesShreveport$56K
- Philip IsherwoodShreveport$4K
- Cheryl SmithShreveport$166
- Susan JuliusBaton Rouge$255K
- Christina JonesSulphur$44K
- Alphonse RoyMetairie$23K
- Indira KailasMarrero$3K
- James ChivertonMetairie$2K
- Anthony PeperoneMandeville$2K
- Brandie SmithCovington$1K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.